Condition: Ectopic Pregnancy · Sponsor: Bagcilar Training and Research Hospital
Study Description (For Patients, Families, and Healthcare Providers) Purpose: The aim of this study is to evaluate the effectiveness and safety of methotrexate treatment in women with ectopic pregnancy who belong to a group for whom this treatment is relatively contraindicated. Background: Methotrexate is a medication commonly used in the treatment of ectopic pregnancy (a pregnancy that occurs outside the uterus, usually in the fallopian tube). However, in certain conditions - such as kidney or liver dysfunction - methotrexate use may carry increased risks. These situations are known as relative contraindications. This study will retrospectively examine treatment outcomes in this specific patient population. Method: The study will analyze medical records of patients who were previously treated with methotrexate for ectopic pregnancy. No new interventions will be performed. The analysis will be based solely on existing clinical data. Why Is This Important? The findings of this study may help us better understand the safety limits of methotrexate therapy and guide healthcare providers in managing similar cases in the future.
This description comes directly from the study's public registry record.
gülhan özüm, md · +905355784928 · gulhanozum86@gmail.com
gülhan özüm · 05355784928 · gulhanozum86@gmail.com
Always discuss trial participation with your own doctor first.
| University of Health Sciences, Training and Research Hospital | Istanbul, Türkiye, Turkey (Türkiye) | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07186127